SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.62+1.6%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cacaito who wrote (12335)11/25/1999 9:03:00 PM
From: franksja  Read Replies (2) of 17367
 
I obtained the PII Trauma report as printed in the Journal of Trauma Injury. It is being provided by XOMA IR upon request. It is 12 pages of heavy science, but even to my untrained eye, it is not whitewash nor hype. I don't believe XOMA has, at any time, mislead any of us. They clearly state in the body of the report that the results were not statistically significant even though there were positive results. Why did they go ahead with the PIII?? In my opinion, they were conducting basic science as opposed to applied science--they were/are looking for an indication (stated endpoints not withstanding). When they didn't find it in the early going of the PIII, they shut it down and saved the money. XOMA is apparently continuing to examine the results, looking for an indication. The complications from trauma can come from other causes including, gram positive bacteria etc. XOMA had already tested against gram negative bacteria and I am confident they saw no need to spend more money on those specific tests for LPS. I note that overall, 92% of patients in the placebo group and 95% in the rBPI patients received systemic antibiotics within the first 15 days of the study. The proportion of patients who developed at least one serious infection through day 15 was 35% in the placebo group and 31% in the rBPI group. Pneumonia was the most common serious infection and showed the greatest difference between the two treatment groups through day 15: 28% in the placebo group versus 20% in the rBPI group. Pneumonia caused by gram-negative organisms occurred in 20% of placebo patients and 14% of rBPI patients. Jim Franks
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News